An empirical comparison of low-dose extrapolation from points of departure (PoD) compared to extrapolations based upon methods that account for model uncertainty

Risk Evaluation Branch, National Institute for Occupational Safety and Health, 4626 Columbia Parkway, Cincinnati, Ohio 45226, USA. Electronic address: .
Regulatory Toxicology and Pharmacology (Impact Factor: 2.03). 07/2013; 67(1). DOI: 10.1016/j.yrtph.2013.06.006
Source: PubMed


Experiments with relatively high doses are often used to predict risks at appreciably lower doses.A point of departure (PoD) can be calculated as the dose associated with a specified moderate response level that is often in the range of experimental doses considered. A linear extrapolation to lower doses often follows.An alternative to the PoD method is to develop a model that accounts for the model uncertainty in the dose-response relationship and to use this model to estimate the risk at low doses.Two such approaches that account for model uncertainty are model averaging (MA) and semi-parametric methods.We use these methods, along with the PoD approach in the context of a large animal (40,000+ animal) bioassay that exhibited sub-linearity. When models are fit to high dose data and risks at low doses are predicted, the methods that account for model uncertainty produce dose estimates associated with an excess risk that are closer to the observed risk than the PoD linearization.This comparison provides empirical support to accompany previous simulation studies that suggest methods that incorporate model uncertainty provide viable, and arguably preferred, alternatives to linear extrapolation from a PoD.

12 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The basic conclusions in almost all reports on new drug applications and in all publications in toxicology are based on statistical methods. However, serious contradictions exist in practice: designs with small samples sizes but use of asymptotic methods (i.e. constructed for larger sample sizes), statistically significant findings without biological relevance (and vice versa), proof of hazard vs. proof of safety, testing (e.g. no observed effect level) vs. estimation (e.g. benchmark dose), available statistical theory vs. related user-friendly software. In this review the biostatistical developments since about the year 2000 onwards are discussed, mainly structured for repeated-dose studies, mutagenicity, carcinogenicity, reproductive and ecotoxicological assays. A critical discussion is included on the unnecessarily conservative evaluation proposed in guidelines, the inadequate but almost always used proof of hazard approach, and the limitation of data-dependent decision-tree approaches.
    08/2014; 3(6). DOI:10.1039/C4TX00047A

  • Wiley StatsRef: Statistics Reference Online, 09/2015: pages 1-8; , ISBN: 9781118445112